Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Durvalumab & Non-small-cell lung cancer (NSCLC), Durvalumab is approved by both the FDA and EMA for the treatment of unresectable, locally advanced stage III Non-small-cell lung cancer (NSCLC), specifically as consolidation therapy following chemoradiation. This approval was based on the pivotal PACIFIC trial, which demonstrated that durvalumab significantly improves progression-free survival and overall survival compared to standard of care in this patient…